Joel M. Gelfand MD, MSCE, is a professor of dermatology and epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also vice chair of clinical research, medical director of the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials.
Dr Gelfand is the author of over 260 scientific publications, editorials, reviews, and text book chapters (cited >18,000 times, H index 60), which appear in journals such as Journal of the American Medical Association (JAMA), British Medical Journal (BMJ), European Heart Journal (EHJ), Annals of the Rheumatic Diseases (ARD), JAMA Dermatology, Journal of the American Academy of Dermatology (JAAD), and the Journal Investigative Dermatology (JID). He is a past associate editor of Pharmacoepidemiology and Drug Safety, past editorial board member of JAAD, and is currently the deputy editor of JID.
Dr Gelfand is the recipient of the American Skin Association’s Psoriasis Achievement Award, Penn’s New Investigator Marjorie Bowman Award, Lady Barbara Colyton’s Award for Autoimmune Research, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, National Psoriasis Foundation’s (NPF) inaugural award for scientific achievement, and is an elected member of the American Society for Clinical Investigation. He co-chairs the NPF’s COVID-19 task force and is a member of the board of directors for the International Psoriasis Council.
Dr Gelfand is a co-author of the American Academy of Dermatology (AAD)-NPF joint guidelines of care for psoriasis. He has given more than 10 named lectureships and keynote addresses, including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the AAD’s Marion B. Sulzberger lecture. He has received grant support from the National Institutes of Health (NIH), US Food and Drug Administration (FDA), Patient-Centered Outcomes Research Institute (PCORI), the Dermatology Foundation, the American Skin Association, the NPF, and numerous pharmaceutical companies to support his independent research program.
The overarching goal of Dr Gelfand’s research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, cardiovascular disease, and mortality.